# A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Source: https://onco.cc/trials/nct07668752/  
OnCo record `nct07668752` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing GFH375 in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation is a phase 3 interventional study registered as NCT07668752, led by Genfleet Therapeutics (Shanghai), and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy. Planned enrolment is 300 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07668752
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy
- Sponsor: Genfleet Therapeutics (Shanghai)
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07668752: https://clinicaltrials.gov/study/NCT07668752

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [GFH375](https://onco.cc/drugs/gfh375/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)

---
JSON: https://onco.cc/api/v1/entities/nct07668752.json